Context Therapeutics Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on development of medicines and novel therapies for the treatment of female cancer patients. Context Therapeutics serves customers in the United States.

S-3 | Registration statement for specified transactions by certain issuers

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Context Therapeutics (CNTX US)

S-3 | Registration statement for specified transactions by certain issuers

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-09-23)

Current Report (Form 8-K | Period ending 2024-09-17)

Current Report (Form 8-K | Period ending 2024-09-04)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)